A US Food and Drug Administration advisory panel expressed conflicting views on whether FDA should act to restrict the use of higher dosage strengths of opioid analgesics. Several argued there is no compelling reason for these concentrations since patients can simply take more lower dose pills. But most members agreed that these dosages should remain available to a subset of patients.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?